The transthyretin Tyr77 variant of familial amyloid polyneuropathy (FAP) has been identified in a few North American and European patients, but the full spectrum of its clinical manifestations is still not known. We report a 3-generation family of Jewish-Yemenite origin with Tyr77 FAP presenting with atypical features. The affected individuals had sensorimotor and autonomic neuropathy and cardiomyopathy accompanied by prominent dysphagia, hearing loss and asymptomatic carpal tunnel syndrome. Brain MRI in the proband showed multifocal white matter lesions. These features extend the reported Tyr77 phenotype and support the modifying effect of additional factors on the disease expression.

Keywords:
Familial amyloid polyneuropathy, Transthyretin
1.
Hund E, Linke RP, Willing F, Grau A: Transthyretin-associated neuropathic amyloidosis: Pathogenesis and treatment. Neurology 2001;56:431–435.
2.
Saraiva MJM: Transthyretin mutations in hyperthyroxinemia and amyloid disease. Hum Mutat 2001;17:493–503.
3.
Herrick MK, DeBruyne K, Horoupian DS, Skare J, Vanefsky MA, Ong T: Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene. Neurology 1996;47:988–992.
4.
Gertz MA, Kyle RA, Thibodeau SN: Familial amyloidosis: A study of 52 North American-born patients examined during a 30-year period. Mayo Clin Proc 1992;67:428–440.
5.
Reilly MM, Adams D, Davis MB, Said G, Harding AE: Haplotype analysis of French, British and other European patients with familial amyloid polyneuropathy (met 30 and tyr 77). J Neurol 1995;242:664–668.
6.
Blanco-Jerez CR, Jimenez-Escrig A, Gobernado JM, Lopez-Calvo S, De Blas G, Redondo C, Villanueva MG, Orennsanz L: Transthyretin Tyr77 familial amyloid polyneuropathy: A clinicopathological study of a large kindred. Muscle Nerve 1998;21:1478–1485.
7.
Libbey CA, Rubinow A, Shirahama T, Deal C, Cohen AS: Familial amyloid polyneuropathy. Demonstration of prealbumin in a kinship of German/English ancestry with onset in the seventh decade. Am J Med 1984;76:18–24.
8.
Satier F, Nichols WC, Benson MD: Diagnosis of familial amyloidotic polyneuropathy in France. Clin Genet 1990;38:469–473.
9.
Bhatia K, Reilly M, Adams D, Davis MB, Hawkes CH, Thomas PK, Said G, Harding AE: Transthyretin gene mutations in British and French patients with amyloid neuropathy. J Neurol Neurosurg Psychiatry 1993;56:694–697.
10.
Quan D, Cohen JA: Clinical variant of familial amyloid polyneuropathy. Muscle Nerve 2002;26:417–420.
11.
Wallace MR, Dwulet FE, Williams EC, Conneally PM, Benson MD: Identification of a new hereditary amyloidosis prealbumin variant, Tyr-77, and detection of the gene by DNA analysis. J Clin Invest 1988;81:189–193.
12.
Ii S, Minnerath S, Ii K, Dyke PJ, Sommer SS: Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations. Neurology 1991;41:893–898.
13.
Reilly M, Adams D, Booth DR, Davis MB, Said G, Laubriat-Bianchin M, Pepys MB, Thomas PK, Harding AE: Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain 1995;118:849–856.
14.
Adams D, Said G: Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies. J Neurol 1996;243:63–67.
15.
Plante-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G: Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998;51:708–714.
16.
Nichols WC, Benson MD: Hereditary amyloidosis: Detection of variant prealbumin genes by restriction enzyme analysis of amplified genomic DNA sequences. Clin Genet 1990;37:44–53.
17.
Ikeda K, Kinoshita M, Takamiya K, Iwasaki Y, Tomita Y, Nakano I, Nakazato M: Bulbar palsy in senile onset familial amyloid polyneuropathy (30Val-Met): Transthyretin-amyloid deposits in the hypoglossal nerve root. Eur J Neurol 1998;5:211–214.
18.
Coelho T: Familial amyloid polyneuropathy: New developments in genetics and treatment. Curr Opin Neurol 1996;9:355–359.
19.
Klein CJ, Nakumura M, Jacobson DR, Lacy MQ, Benson MD, Petersen RC: Transthyretin amyloidosis (serine 44) with headache, hearing loss, and peripheral neuropathy. Neurology 1998;51:1462–1464.
20.
Garzuly F, Wisniewski T, Brittig F, Budka H: Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 1996;47:1562–1567.
21.
Goren H, Steinberg MC, Farboody GH: Familial oculoleptomeningeal amyloidosis. Brain 1980;103:473–495.
22.
Petersen RB, Goren H, Cohen M, Richardson SL, Tresser N, Lynn A, Gali M, Estes M, Gambetti P: Transthyretin amyloidosis: A new mutation associated with dementia. Ann Neurol 1997;41:307–313.
23.
Mascalchi M, Salvi F, Pirini MG, D’Errico A, Ferlini A, Lolli F, Plasmati R, Tessa C, Villari N, Tassinari CA: Transthyretin amyloidosis and superficial siderosis of the CNS. Neurology 1999;53:1498–1503.
24.
Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD: Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol 1999;56:1152–1155.
25.
Jacobson DR, Rosenthal CJ, Buxbaum JN: Transthyretin Pro36 associated with familial amyloidotic polyneuropathy in an Ashkenazi Jewish kindred. Hum Genet 1992;90:158–160.
26.
Jacobson DR, Buxbaum JN: A double-variant transthyretin allele (Ser6, Ile33) in the Israeli patient ‘SKO’ with familial amyloidotic polyneuropathy. Hum Mutat 1994;3:254–260.
27.
Zlotogora J, Bach G, Munnich A: Molecular basis of mendelian disorders among Jews. Mol Genet Metab 2000;69:169–180.
28.
Goldberg-Stern H, D’jaldetti R, Melamed E, Gadoth N: Machado-Joseph (Azorean) disease in a Yemenite Jewish family in Israel. Neurology 1994;44:1298–1301.
29.
Benson MD II, Turpin JC, Lucotte G, Zeldenrust S, LeChevalier B, Benson MD: A transthyretin variant (alanine 71) associated with familial amyloidotic polyneuropathy in a French family. J Med Genet 1993;30:120–122.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.